Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 3
555
about 3.6 years
12–100
36 sites in AL, AZ, CA +15
What this study is about
This trial is testing a treatment called remibrutinib compared to placebo in adults with moderate to severe hidradenitis suppurativa. The goal is to see if this treatment is effective, safe, and well-tolerated.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo 1
- 2.Take Placebo 2
- 3.Take Remibrutinib Dose A
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Tablet)
Secondary: Incidence of treatment emergent adverse events and serious adverse events during the study, Percentage change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16, Proportion of participants with clinical response in HS related skin pain (NRS 30), at worst at Week 16